12.03.21
Amyris, Inc. announced strong year-over-year consumer sales performance during this year's Black Friday sales week.
Consumer sales for Black Friday week exceeded $10 million, more than doubling last year's performance and representing the best week of Amyris consumer sales on record. With a record 791,000 consumer visits to Amyris' direct-to-consumer websites during the week, approximately 50% of consumer sales came from online channels.
Amyris’s consumer brands in beauty and personal care include Biossance, Pipette, Olika, Costa Brazil, Rose Inc, Terasana, JVN and EcoFabulous.
"All our consumer brands and channels demonstrated a very strong performance during Black Friday sales week, setting new consumer sales records for orders shipped and new consumers coming to our brands," commented John Melo, president and CEO of Amyris. "With advance holiday season planning and solid execution, we have been able to work through the supply chain challenges thus far this quarter and meet strong demand for our consumer products.
In addition to the solid sales performance, Melo says Amyris ais focused on the successful completion of human trials in South Africa so it can move to regulatory approval and commercialization of its COVID-19 RNA vaccine.
Consumer sales for Black Friday week exceeded $10 million, more than doubling last year's performance and representing the best week of Amyris consumer sales on record. With a record 791,000 consumer visits to Amyris' direct-to-consumer websites during the week, approximately 50% of consumer sales came from online channels.
Amyris’s consumer brands in beauty and personal care include Biossance, Pipette, Olika, Costa Brazil, Rose Inc, Terasana, JVN and EcoFabulous.
"All our consumer brands and channels demonstrated a very strong performance during Black Friday sales week, setting new consumer sales records for orders shipped and new consumers coming to our brands," commented John Melo, president and CEO of Amyris. "With advance holiday season planning and solid execution, we have been able to work through the supply chain challenges thus far this quarter and meet strong demand for our consumer products.
In addition to the solid sales performance, Melo says Amyris ais focused on the successful completion of human trials in South Africa so it can move to regulatory approval and commercialization of its COVID-19 RNA vaccine.